Lung-Resident Memory Th2 Cells in Asthma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03455959|
Recruitment Status : Recruiting
First Posted : March 7, 2018
Last Update Posted : October 26, 2020
|Condition or disease||Intervention/treatment||Phase|
|Asthma, Allergic||Procedure: Bronchoscopy/BAL Procedure: Airway Brushing||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||A single time point study with all information obtained at the time of bronchoscopy|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Lung-Resident Memory Th2 Cells in Asthma|
|Actual Study Start Date :||May 23, 2019|
|Estimated Primary Completion Date :||December 2022|
|Estimated Study Completion Date :||December 2023|
Experimental: Allergic Asthmatic or Healthy Control Adults
Allergic Asthmatic or Healthy Control Adults will undergo Bronchoscopy/BAL and airway brushing
Participants will receive 2-3 inhalations(90 ug ea)of albuterol to minimize bronchoconstriction.Medication includes midazolam by intravenous injection, and fentanyl by intravenous injection as judged necessary.4% lidocaine is delivered via atomizer spray to the oral pharynx for local anesthesia.1% lidocaine is delivered through the bronchoscope to the vocal cords and lung segments for local anesthesia.The bronchoscope is then passed through the vocal cords into the trachea.Throughout the procedure,all participants will have continuous blood pressure,heart rate,and oxygen saturation monitoring.Participants will be instructed to relate any discomfort or problems through a series of standardized hand signals.Once in the lung, aliquots of sterile saline are instilled into a subsegment of the lingula of the left lung and withdrawn into a trap by gentle suction. Then,the bronchoscope is passed into a subsegment of the right upper lobe and the right middle lobe where the lavage is repeated.
Procedure: Airway Brushing
After completion of the BALs, endobronchial brushing of the airways will be performed using the airway brushings with a Conmed Harrell™ 4 mm unsheathed cytology brush. Upon completing the brushing the investigators remove the bronchoscope with the brush in place to avoid shearing off isolated cells. The brush will be gently glided back and forth on the airway epithelium 10 times in 2 different locations within the same airway. The brush is then placed in media and flicked to remove the cells. There is some airway bleeding caused by the procedure, and participants are made aware that they may cough up small amounts of blood for 24-48 hours following the procedure.
- The phenotype of Th2-Trm recovered from the airway mucosa [ Time Frame: This is a single time point study with all information obtained at the time of bronchoscopy defined as Day 0. ]The investigators will determine the phenotype of Th2-Trm recovered from the airway mucosa of humans with asthma via flow cytometry to define the phenotype of human Th2-Trm. The T cells will be recovered from airway bronchial brushing samples of patients with allergic asthma and allergy to an indoor allergen, and the investigators will obtain comparative samples from nonallergic healthy control subjects.
- The transcriptional profile of Th2-Trm recovered from the airway mucosa [ Time Frame: This is a single time point study with all information obtained at the time of bronchoscopy defined as Day 0. ]The investigators will determine the transcriptional profile of Th2-Trm recovered from the airway mucosa of humans with asthma via single-cell RNA-seq analysis to define the phenotype of human Th2-Trm. The T cells will be recovered from airway bronchial brushing samples of patients with allergic asthma and allergy to an indoor allergen, and the investigators will obtain comparative samples from nonallergic healthy control subjects.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03455959
|Contact: Daniel L Hamilosemail@example.com|
|Contact: Ben D Medoff||(617) firstname.lastname@example.org|
|United States, Massachusetts|
|Massachusetts General Hospital||Recruiting|
|Boston, Massachusetts, United States, 02116|
|Contact: Daniel L Hamilos, MD 617-726-5090 email@example.com|
|Principal Investigator:||Andrew D Luster||MGH|